Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Abbreviated Injury Scale

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44258   clinical trials with a EudraCT protocol, of which   7344   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: Abbreviated Injury Scale. Displaying page 1 of 1.
    EudraCT Number: 2022-003382-38 Sponsor Protocol Number: FSNANO05012022 Start Date*: 2023-01-12
    Sponsor Name:FSNANO05012022
    Full Title: Efficacy and safety of Cerebrolysin for neurorecovery after moderate-severe traumatic brain injury
    Medical condition: Moderate-severe traumatic brain injury
    Disease: Version SOC Term Classification Code Term Level
    26.1 10022117 - Injury, poisoning and procedural complications 10060690 Traumatic brain injury LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-005574-11 Sponsor Protocol Number: Pennsaid-2014/P-3-01 Start Date*: 2015-06-18
    Sponsor Name:Nuvo Research GmbH
    Full Title: A randomized, double-blind, multi-center, placebo-controlled, parallel group study to evaluate the efficacy and safety of an Diclofenac 2% (w/w) cutaneous solution applied twice daily in patients w...
    Medical condition: Treatment of pain and Inflammation associated Acute Soft Tissue Injury/Ankle Sprain
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004863 10002549 Ankle sprain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001720-30 Sponsor Protocol Number: DRO-200/II/14/1 Start Date*: 2014-09-23
    Sponsor Name:Drossapharm AG
    Full Title: A randomized, double-blind, multi-center, placebo-controlled, parallel group study to evaluate the efficacy and safety of an etofenamate 5% (EFM) cutaneous patch applied twice daily in patients wit...
    Medical condition: Ankle sprain, Grade I or II
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004812-81 Sponsor Protocol Number: 2019-48 Start Date*: 2021-03-05
    Sponsor Name:ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE
    Full Title: Ketamine Low dOse Evaluation on morphine consumption in traumatic patient : a prospective randomized controlled double-blind study
    Medical condition: Traumatism
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-002584-27 Sponsor Protocol Number: AC-054-301 Start Date*: 2007-11-07
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-caus...
    Medical condition: Indication: Aneurysmal subarachnoid hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042318 Subarachnoid haemorrhage NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) FI (Completed) SE (Completed) DE (Completed) AT (Completed) DK (Completed) ES (Completed) CZ (Completed) IT (Completed) SI (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2021-005388-32 Sponsor Protocol Number: ACP-103-070 Start Date*: 2022-07-05
    Sponsor Name:Acadia Pharmaceuticals Inc.
    Full Title: A 52-Week Open-Label Extension Study of Pimavanserin in Children and Adolescents with Irritability Associated with Autism Spectrum Disorder (ASD)
    Medical condition: Irritability associated with autistic disorder in children and adolescents with ASD
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10063844 Autism spectrum disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005387-22 Sponsor Protocol Number: ACP-103-069 Start Date*: 2022-06-27
    Sponsor Name:Acadia Pharmaceuticals Inc.
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder
    Medical condition: Treatment of irritability associated with autistic disorder in children and adolescents with ASD
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10063844 Autism spectrum disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed) HU (Ongoing) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006785-29 Sponsor Protocol Number: AC-054-302 Start Date*: 2009-09-15
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-caus...
    Medical condition: Indication: Subarachnoid aneurysmal hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    11 10042316 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended) FI (Prematurely Ended) AT (Prematurely Ended) BE (Completed) CZ (Completed) FR (Completed) DE (Completed) SI (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA